Liposomal system for drug delivery
A liposomal system for delivery of an active agent comprising: lipid component forming a liposome; destabilizing agent associated with the lipid component, the destabilizing agent capable of forming reactive oxygen species to oxidise unsaturated lipids and destabilise liposomal membrane; and an active agent; wherein the active agent is releasable from the liposome by exposure to high energy electromagnetic radiation.
1. A liposomal system for delivery of an active agent, the system comprising:
a liposome comprising an outer lipid bilayer component;
a destabilizing agent embedded inside the lipid bilayer component, the destabilizing agent capable of forming reactive oxygen species to oxidise unsaturated lipids and destabilise liposomal membranes; and
an active agent in the liposome;
wherein the active agent is releasable from the liposome by exposure to high energy electromagnetic radiation; and
wherein the destabilizing agent consists of:
a metal nanoparticle selected from the group consisting of gold, silver and bismuth or a cerium fluoride (CeF 3 ) inorganic nanoparticle, and
a photosensitizer selected from the group consisting of verteporfin, rose bengal, aminolevulinic acid, and porfimer sodium.
2. The liposomal system according to claim 1 wherein the lipid bilayer component comprises naturally occurring lipids.
3. The liposomal system according to claim 1 wherein the lipid bilayer component comprises 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1, 2-di-(9Z-octadecenoyl)-3-trimethylammonium-propane (DOTAP), or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA).
4. The liposomal system according to claim 1 wherein the photosensitizer is verteporfin.
5. The liposomal system according to claim 1 wherein the destabilizing agent is a gold nanoparticle and verteporfin.
6. The liposomal system according to claim 1 wherein the active agent is selected from the group consisting of a chemotherapy agent, a pharmaceutical, a medical imaging agent, an antisense oligonucleotide and a small interfering RNA (siRNA) molecule for gene silencing and therapy, a biologically active agent, an antibody, an antibody fragment, a protein, a peptide, and a nucleic acid.
7. The liposomal system according to claim 6 wherein the active agent is a chemotherapy agent selected from the group consisting of doxorubicin, vincristine, 5-fluorouracil and etoposide phosphate.
8. The liposomal system according to claim 7 wherein the chemotherapy agent is doxorubicin.
9. The liposomal system according to claim 6 wherein the active agent is an antisense oligonucleotide.
10. The liposomal system according to claim 1 further comprising an uptake material to cause uptake of the liposome into a target region or target cell of a subject.
11. The liposomal system according to claim 10 wherein the uptake material is selected from the group consisting of an antigen, an antibody, an antibody fragment, a peptide, a hormone, a cytokine, a ligand, and a receptor.
12. The liposomal system according to claim 1 wherein the high energy electromagnetic radiation has a photon energy of at least about 6 MeV.
13. The liposomal system according to claim 12 wherein the high energy electromagnetic radiation is x-ray radiation or gamma-ray radiation.
14. The liposomal system according to claim 1 , wherein the lipid bilayer component comprises one or more selected from the group consisting of phospholipids and cholesterol.
15. A method for administering an active agent to a subject, the method comprising:
(a) providing a liposomal system to a subject, said liposomal system comprising:
a liposome comprising an outer lipid bilayer component;
a destabilizing agent embedded inside the lipid bilayer component, the destabilizing agent capable of forming reactive oxygen species to oxidise unsaturated lipids and destabilise liposomal membranes; and
an active agent in the liposome;
wherein the active agent is releasable from the liposome by exposure to high energy electromagnetic radiation, and
wherein the destabilizing agent consists of:
a metal nanoparticle selected from the group consisting of gold, silver and bismuth or a cerium fluoride (CeF 3 ) inorganic nanoparticle, and
a photosensitizer selected from the group consisting of verteporfin, rose bengal, aminolevulinic acid, and porfimer sodium; and
(b) exposing the subject to high energy electromagnetic radiation to release the active agent from the liposome to treat the subject.
16. The method according to claim 15 wherein the high energy electromagnetic radiation is x-ray radiation or gamma ray radiation.